Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

ClinicalTrials.gov ID: NCT06830798

Public ClinicalTrials.gov record NCT06830798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Study identification

NCT ID
NCT06830798
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
450 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 18, 2025
Primary completion
Nov 29, 2027
Completion
Aug 29, 2028
Last update posted
Jun 17, 2026

2025 – 2028

United States locations

U.S. sites
32
U.S. states
23
U.S. cities
29
Facility City State ZIP Site status
Research Site Phoenix Arizona 85054 Recruiting
Research Site Los Angeles California 90095 Recruiting
Research Site San Francisco California 94115 Withdrawn
Research Site San Francisco California 94143 Recruiting
Research Site Stanford California 94305 Recruiting
Research Site New Haven Connecticut 06510 Recruiting
Research Site Jacksonville Florida 32224 Recruiting
Research Site Tampa Florida 33606 Recruiting
Research Site Atlanta Georgia 30322 Recruiting
Research Site Chicago Illinois 60608 Recruiting
Research Site Chicago Illinois 60637 Recruiting
Research Site Fairway Kansas 66205 Recruiting
Research Site Lexington Kentucky 40508 Recruiting
Research Site Kenner Louisiana 70065 Recruiting
Research Site Ann Arbor Michigan 48109 Recruiting
Research Site Detroit Michigan 48202 Recruiting
Research Site Minneapolis Minnesota 55455 Recruiting
Research Site St Louis Missouri 63108 Recruiting
Research Site Omaha Nebraska 68198 Recruiting
Research Site Livingston New Jersey 07039 Recruiting
Research Site New York New York 10016 Withdrawn
Research Site New York New York 10065 Recruiting
Research Site Durham North Carolina 27705 Recruiting
Research Site Philadelphia Pennsylvania 19140 Recruiting
Research Site Greenville South Carolina 29605 Recruiting
Research Site Nashville Tennessee 37232 Recruiting
Research Site Dallas Texas 75235 Recruiting
Research Site Houston Texas 77030 Recruiting
Research Site Charlottesville Virginia 22908 Recruiting
Research Site Richmond Virginia 23298 Recruiting
Research Site Seattle Washington 98104 Recruiting
Research Site Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06830798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06830798 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →